India Court Ruling Upholds Access To Cheaper Generic Drugs
India’s Supreme Court today rejected efforts by the Swiss drug major Novartis to patent the anticancer drug Gleevec (imatinib mesylate), in a ruling that signaled India’s determination to support affordable medicines. The court rejected the Basel-based company’s challenge to India’s patent law, which limits drug firms’ ability to extend patent life beyond 20 years by making minor modifications to drugs, a tactic known as ‘evergreening’. Novartis’s patent claim on a modified version of Gleevec (marketed in some countries as Glivec) “fails in both the tests of invention and patentability”, the court said....